Skip to main content
Erschienen in: Tumor Biology 4/2016

03.11.2015 | Original Article

Hotspot TERT promoter mutations are rare events in testicular germ cell tumors

verfasst von: Flavio Mavignier Cárcano, Daniel Onofre Vidal, André van Helvoort Lengert, Cristovam Scapulatempo Neto, Luisa Queiroz, Herlander Marques, Fátima Baltazar, Camila Maria da Silva Martinelli, Paula Soares, Eduardo Caetano Albino da Silva, Luiz Fernando Lopes, Rui Manuel Reis

Erschienen in: Tumor Biology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

The abnormal activation of telomerase, codified by the telomerase reverse transcriptase (TERT) gene, is related to one of cancer hallmarks. Hotspot somatic mutations in the promoter region of TERT, specifically the c.-124:C>T and c.-146:C>T, were recently identified in a range of human cancers and have been associated with a more aggressive behavior. Testicular germ cell tumors frequently exhibit a good prognosis; however, the development of refractory disease is still a clinical challenge. In this study, we aim to evaluate for the first time the presence of the hotspot telomerase reverse transcriptase gene promoter mutations in testicular germ cell tumors. A series of 150 testicular germ cell tumor cases and four germ cell tumor cell lines were evaluated by PCR followed by direct Sanger sequencing and correlated with patient’s clinical pathological features. Additionally, we genotyped the telomerase reverse transcriptase gene promoter single nucleotide polymorphism rs2853669 (T>C) located at −245 position. We observed the presence of the TERT promoter mutation in four patients, one exhibited the c.-124:C>T and three the c.-146:C>T. No association between TERT mutation status and clinicopathological features could be identified. The analysis of the rs2853669 showed that variant C was present in 22.8 % of the cases. In conclusion, we showed for the first time that TERT promoter mutations occur in a small subset (~3 %) of testicular germ cell tumors.
Literatur
4.
Zurück zum Zitat Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021–6. doi:10.1073/pnas.1303607110.CrossRefPubMedPubMedCentral Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021–6. doi:10.​1073/​pnas.​1303607110.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Park CK, Lee SH, Kim JY, Kim JE, Kim TM, Lee ST, et al. Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget. 2014;5(10):3399–407.CrossRefPubMedPubMedCentral Park CK, Lee SH, Kim JY, Kim JE, Kim TM, Lee ST, et al. Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget. 2014;5(10):3399–407.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110(43):17426–31. doi:10.1073/pnas.1310522110.CrossRefPubMedPubMedCentral Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110(43):17426–31. doi:10.​1073/​pnas.​1310522110.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Hosen I, Rachakonda PS, Heidenreich B, Sitaram RT, Ljungberg B, Roos G, et al. TERT promoter mutations in clear cell renal cell carcinoma. Int J Cancer. 2014. doi:10.1002/ijc.29279.PubMed Hosen I, Rachakonda PS, Heidenreich B, Sitaram RT, Ljungberg B, Roos G, et al. TERT promoter mutations in clear cell renal cell carcinoma. Int J Cancer. 2014. doi:10.​1002/​ijc.​29279.PubMed
10.
Zurück zum Zitat Bray F, Ferlay J, Devesa SS, McGlynn KA, Moller H. Interpreting the international trends in testicular seminoma and nonseminoma incidence. Nat Clin Pract Urol. 2006;3(10):532–43. doi:10.1038/ncpuro0606.CrossRefPubMed Bray F, Ferlay J, Devesa SS, McGlynn KA, Moller H. Interpreting the international trends in testicular seminoma and nonseminoma incidence. Nat Clin Pract Urol. 2006;3(10):532–43. doi:10.​1038/​ncpuro0606.CrossRefPubMed
11.
Zurück zum Zitat Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol: Off J Am Soc Clin Oncol. 1990;8(11):1777–81.CrossRef Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol: Off J Am Soc Clin Oncol. 1990;8(11):1777–81.CrossRef
12.
Zurück zum Zitat Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(33):4906–11. doi:10.1200/JCO.2009.26.8128.CrossRef Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(33):4906–11. doi:10.​1200/​JCO.​2009.​26.​8128.CrossRef
13.
Zurück zum Zitat Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer. 2005;93(2):178–84. doi:10.1038/sj.bjc.6602682.CrossRefPubMedPubMedCentral Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer. 2005;93(2):178–84. doi:10.​1038/​sj.​bjc.​6602682.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Albanell J, Bosl GJ, Reuter VE, Engelhardt M, Franco S, Moore MA, et al. Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst. 1999;91(15):1321–6.CrossRefPubMed Albanell J, Bosl GJ, Reuter VE, Engelhardt M, Franco S, Moore MA, et al. Telomerase activity in germ cell cancers and mature teratomas. J Natl Cancer Inst. 1999;91(15):1321–6.CrossRefPubMed
16.
Zurück zum Zitat Dirks WG, Faehnrich S, Estella IA, Drexler HG. Short tandem repeat DNA typing provides an international reference standard for authentication of human cell lines. ALTEX. 2005;22(2):103–9.PubMed Dirks WG, Faehnrich S, Estella IA, Drexler HG. Short tandem repeat DNA typing provides an international reference standard for authentication of human cell lines. ALTEX. 2005;22(2):103–9.PubMed
17.
18.
Zurück zum Zitat Campanella NC, Celestino R, Pestana A, Scapulatempo-Neto C, de Oliveira AT, Brito MJ, et al. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur J Hum Genet: EJHG. 2014. doi:10.1038/ejhg.2014.195.PubMedCentral Campanella NC, Celestino R, Pestana A, Scapulatempo-Neto C, de Oliveira AT, Brito MJ, et al. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs). Eur J Hum Genet: EJHG. 2014. doi:10.​1038/​ejhg.​2014.​195.PubMedCentral
19.
Zurück zum Zitat Campanella NC, Penna V, Abrahao-Machado LF, Cruvinel-Carloni A, Ribeiro G, Soares P, et al. TERT promoter mutations in soft tissue sarcomas. Int J Biol Markers. 2015. doi:10.5301/jbm.5000168. Campanella NC, Penna V, Abrahao-Machado LF, Cruvinel-Carloni A, Ribeiro G, Soares P, et al. TERT promoter mutations in soft tissue sarcomas. Int J Biol Markers. 2015. doi:10.​5301/​jbm.​5000168.
20.
Zurück zum Zitat IGCCCG. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. Int Germ Cell Cancer Collab Group J Clin Oncol: Off J Am Soc Clin Oncol. 1997;15(2):594–603. IGCCCG. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. Int Germ Cell Cancer Collab Group J Clin Oncol: Off J Am Soc Clin Oncol. 1997;15(2):594–603.
21.
Zurück zum Zitat Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218. doi:10.1038/ncomms3218.CrossRefPubMedPubMedCentral Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218. doi:10.​1038/​ncomms3218.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Populo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and x-irradiation. J Invest Dermatol. 2014. doi:10.1038/jid.2014.163.PubMed Populo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and x-irradiation. J Invest Dermatol. 2014. doi:10.​1038/​jid.​2014.​163.PubMed
25.
Zurück zum Zitat Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(13):2129–36. doi:10.1200/JCO.2008.18.8623.CrossRef Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(13):2129–36. doi:10.​1200/​JCO.​2008.​18.​8623.CrossRef
26.
Zurück zum Zitat Sommerer F, Hengge UR, Markwarth A, Vomschloss S, Stolzenburg JU, Wittekind C, et al. Mutations of BRAF and RAS are rare events in germ cell tumours. Int J Cancer. 2005;113(2):329–35. doi:10.1002/ijc.20567.CrossRefPubMed Sommerer F, Hengge UR, Markwarth A, Vomschloss S, Stolzenburg JU, Wittekind C, et al. Mutations of BRAF and RAS are rare events in germ cell tumours. Int J Cancer. 2005;113(2):329–35. doi:10.​1002/​ijc.​20567.CrossRefPubMed
27.
Zurück zum Zitat Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch: Int J Pathol. 2014;465(2):119–33. doi:10.1007/s00428-014-1608-4.CrossRef Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch: Int J Pathol. 2014;465(2):119–33. doi:10.​1007/​s00428-014-1608-4.CrossRef
28.
29.
Zurück zum Zitat Dolci S, Levati L, Pellegrini M, Faraoni I, Graziani G, Di Carlo A, et al. Stem cell factor activates telomerase in mouse mitotic spermatogonia and in primordial germ cells. J Cell Sci. 2002;115(Pt 8):1643–9.PubMed Dolci S, Levati L, Pellegrini M, Faraoni I, Graziani G, Di Carlo A, et al. Stem cell factor activates telomerase in mouse mitotic spermatogonia and in primordial germ cells. J Cell Sci. 2002;115(Pt 8):1643–9.PubMed
30.
Zurück zum Zitat Schrader M, Burger AM, Muller M, Krause H, Straub B, Smith GL, et al. Quantification of human telomerase reverse transcriptase mRNA in testicular germ cell tumors by quantitative fluorescence real-time RT-PCR. Oncol Rep. 2002;9(5):1097–105.PubMed Schrader M, Burger AM, Muller M, Krause H, Straub B, Smith GL, et al. Quantification of human telomerase reverse transcriptase mRNA in testicular germ cell tumors by quantitative fluorescence real-time RT-PCR. Oncol Rep. 2002;9(5):1097–105.PubMed
33.
Zurück zum Zitat Ries LAG YJ, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07–6215, Bethesda, MD, 2007; p165-70. 2007. Ries LAG YJ, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07–6215, Bethesda, MD, 2007; p165-70. 2007.
34.
Zurück zum Zitat Lopes LF, Macedo CR, Pontes EM, Dos Santos AS, Mastellaro MJ, Melaragno R, et al. Cisplatin and etoposide in childhood germ cell tumor: Brazilian pediatric oncology society protocol GCT-91. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(8):1297–303. doi:10.1200/JCO.2008.16.4202.CrossRef Lopes LF, Macedo CR, Pontes EM, Dos Santos AS, Mastellaro MJ, Melaragno R, et al. Cisplatin and etoposide in childhood germ cell tumor: Brazilian pediatric oncology society protocol GCT-91. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(8):1297–303. doi:10.​1200/​JCO.​2008.​16.​4202.CrossRef
Metadaten
Titel
Hotspot TERT promoter mutations are rare events in testicular germ cell tumors
verfasst von
Flavio Mavignier Cárcano
Daniel Onofre Vidal
André van Helvoort Lengert
Cristovam Scapulatempo Neto
Luisa Queiroz
Herlander Marques
Fátima Baltazar
Camila Maria da Silva Martinelli
Paula Soares
Eduardo Caetano Albino da Silva
Luiz Fernando Lopes
Rui Manuel Reis
Publikationsdatum
03.11.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4317-y

Weitere Artikel der Ausgabe 4/2016

Tumor Biology 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.